Peter Libby: Mast Cells in Cardiovascular Disease
Peter Libby, Mallinckrodt Professor of Medicine and Cardiovascular Specialist at Harvard Medical School and Mass General Brigham Hospital, shared a post on LinkedIn:
“Every leukocyte class shall have its day in atherosclerosis. With an international team, we summarize the current evidence supporting mechanisms by which mast cells can participate in this disease. Inflammation has many faces, and reaginic antibody (IgEs) can link adaptive to innate immunity unleashing a multitude of mast cell mediators that can modulate arterial and microvascular biology.”
Title: Mast cells in cardiovascular disease: Fibrosis, angiogenesis and atherogenesis
Authors: Gabriel Bueno, Ilze Bot, Anish A. Kanhai, Roberta Stilhano, Peter Libby, Guido R.Y. De Meyer, Leonardo Martin
Stay informed with Hemostasis Today.
-
Apr 22, 2026, 04:43Ifeanyichukwu Ifechidere: The Critical Role of Calibrator Specificity in Anticoagulation Monitoring
-
Apr 22, 2026, 04:13Ilenia Calcaterra: Clinical Relevance of Persistent Pain in Emicizumab-Treated Haemophilia A
-
Apr 22, 2026, 03:56Annette Bowyer: Reflecting on Progress and Leadership in Laboratory Sciences
-
Apr 21, 2026, 21:07Tareq Abadl: Not Every Low Platelet Count Is True – Check the Smear First
-
Apr 21, 2026, 21:05Beverley Hunt: Honored to Receive the Lifetime Achievement Award at BSH 2026
-
Apr 21, 2026, 21:03Toong Youttananukorn: Proud to Support Data That Drives Action at WFH 2026
-
Apr 21, 2026, 20:48Ney Carter Borges: Endothelial Senescence as a Central Driver of Adipose Dysfunction in Heart Failure and Type 2 Diabetes
-
Apr 21, 2026, 20:29Can Stem Cell-Delivered Platelets Fight Drug-Resistant Bacteria?- RPTH Journal
-
Apr 21, 2026, 18:51WHO Expert Lorenzo Moja Discusses How Essential Medicines Policy Expands Access to Treatment – WFH